

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/225.478	04/08/1994	DONALD B. KOHN		9305
27162	7590 09/01/2004		EXAMINER	
CARELLA, BYRNE, BAIN, GILFILLAN, CECCHI,			WEHBE, ANNE MARIE SABRINA	
STEWART & 5 BECKER FA			ART UNIT	PAPER NUMBER
ROSELAND, NJ 07068			1632	50
DATE MAILED: 0		DATE MAILED: 09/01/2004	4	

Please find below and/or attached an Office communication concerning this application or proceeding.

·					
	Application No.	Applicant(s)			
	08/225,478	KOHN ET AL.			
Office Action Summary	Examiner	Art Unit			
	Anne Marie S. Wehbe	1632			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on					
2a) This action is FINAL . 2b) ☐ This	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4) ⊠ Claim(s) 1-15 and 21-26 is/are pending in the a 4a) Of the above claim(s) is/are withdray 5) ⊠ Claim(s) 6-15, and 23-26 is/are allowed. 6) ⊠ Claim(s) 1-3,5,21 and 22 is/are rejected. 7) ⊠ Claim(s) 4 is/are objected to. 8) □ Claim(s) are subject to restriction and/o	wn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplished any accomplished any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine 1.	epted or b) objected to by the liderawing(s) be held in abeyance. See ion is required if the drawing(s) is object.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority documents application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati ity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary				
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate ratent Application (PTO-152)			

DETAILED ACTION

A Decision on Appeal by the Board of Patent Appeals and Interferences was mailed to the applicants on 3/31/04. In the Decision, the Board reversed the rejection of appealed claims 1-5 and 21-22 under 35 U.S.C. 112, first paragraph, made by the previous examiner of record. This examiner of record in this case has changed, see page 4. In reviewing the application for allowance, the new examiner of record identified prior art not previously made of record which applies to instant claims 1-3, 5, and 21-22. As a result, prosecution in this case has been reopened and the finality of the office action mailed to applicants on 8/20/98 has been withdrawn. Claims 1-15 and 21-26 are pending in the instant application.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the

Application/Control Number: 08/225,478

Art Unit: 1632

reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 1-3, 5, and 21-22 are newly rejected under 35 U.S.C. 102(e) as being anticipated by U.S. Patent No. 5,911,983 (6/15/99), hereafter referred to as Barranger et al.. The applicant claims a method of expressing a therapeutic agent in a human comprising administering autologous CD34+ cells obtained from cord blood to said human, said autologous CD34+ cells having been genetically engineered to include at least once nucleic acid encoding a therapeutic agent. The applicant further claims said methods wherein the nucleic acid is contained in a retroviral vector, or wherein the CD34+ cells are administered in an amount from about 5X10⁵ /kg- 5X10⁶/kg.

Barranger et al. teaches methods for providing biologically active glucocerebrosidase to an individual with Gaucher disease comprising isolating autologous human CD34+ hematopoietic progenitor cells, transducing the cells with a retroviral vector encoding glucocerebrosidase, and transplanting the transduced cells back into the individual with Gaucher disease (Barranger et al., column 28, claims 13-16). While the claims in the Barranger patent recite that the human CD34+ cells are derived from bone marrow, the specification clearly teaches that other sources of human CD34+ cells can be used in the methods of treating Gaucher disease, including CD34+ cells derived from cord blood as exemplified in Figure 28 (see also Barranger et al., column 6). In addition, Barranger et al. teaches that the reintroduction of 2X10⁶ /kg CD34+ cells into patients (Barranger et al., column 26, lines 55-64). Thus, by teaching all the limitations of the claims as written, Barranger et al. anticipates the instant invention as claimed.

Application/Control Number: 08/225,478

Art Unit: 1632

Page 4

Claim 4 is objected to as being dependent upon a rejected base claim, but would be

allowable if rewritten in independent form including all of the limitations of the base claim and

any intervening claims.

Claims 6-15 and 23-26 are considered free of the prior art of record and allowable at this

time.

Any inquiry concerning this communication from the examiner should be directed to

Anne Marie S. Wehbé, Ph.D., whose telephone number is (571) 272-0737. The examiner can be

reached Monday- Friday from 10:30-7:00 EST. If the examiner is not available, the examiner's

supervisor, Amy Nelson, can be reached at (571) 272-0804. For all official communications, the

technology center fax number is (703) 872-9306. For informal, non-official communications

only, the examiner's direct fax number is (571) 273-0737.

Dr. A.M.S. Wehbé

ANNE M. WEHBE' PH.D
PRIMARY EXAMINER

JASEMINE C. CHAMBERS
DIRECTOR

Jasemin C. Clamber

TECHNOLOGY CENTER 1600